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One titrimetric and two spectrophotometric methods have been described for the determination of 
ofloxacin (OFX) in bulk drug and in tablets, employing N-Bromosuccinimide as an analytical reagent. 
The proposed methods involve the addition of a known excess of NBS to OFX in acid medium, followed 
by determination of unreacted NBS. In titrimetry, the unreacted NBS is determined iodometrically, and 
in spectrophotometry, unreacted NBS is determined by reacting with a fixed amount of either indigo 
carmine (Method A) or metanil yellow (Method B). In all the methods, the amount of NBS reacted 
corresponds to the amount of OFX. Titrimetry allows the determination of 1-8 mg of OFX and the 
calculations are based on a 1:5 (OFX:NBS) reaction stoichiometry. In spectrophotometry, Beer’s law is 
obeyed in the concentration ranges 0.5-5.0 µg/mL for method A and 0.3-3.0 µg/mL for method B. The 
molar absorptivities are calculated to be 5.53x104 and 9.24x104 L/mol/cm for method A and method B, 
respectively. The methods developed were applied to the assay of OFX in tablets, and results compared 
statistically with those of a reference method. The accuracy and reliability of the methods were further 
ascertained by performing recovery tests via the standard-addition method.
Uniterms: Ofloxacin/determination. Titrimetry/quantitative analysis. Spectrophotometry/quantitative 
analysis. N-Bromosuccinimide. Tablets/quantitative analysis.
Descrevem-se métodos, um titulométrico e dois espectrofotométricos, para a determinação de ofloxacino 
(OFX) na matéria-prima e em comprimidos, empregando a N-bromossuccinimida (NBS) como reagente 
analítico. Os métodos propostos envolvem a adição de excesso conhecido de NBS ao OFX, em meio 
ácido, seguida de determinação do NBS que não reagiu. Na titulometria, o NBS que não reagiu é 
determinado iodometricamente e na espectrofotometria, o NBS que não reagiu é determinado pela reação 
com quantidade fixa de índigo carmim (Método A) ou amarelo de metanila (Método B). Em todos os 
métodos, a quantidade de NBS que reagiu corresponde à quantidade de OFX. A titulometria permite a 
determinação de 1-8 mg de OFX e os cálculos se baseiam na estequiometria de reação de 1:5 (OFX:NBS). 
Na espectrofotometria, a Lei de Beer é obedecida nas faixas de concentração de 0,5-5,0 μg/mL, para 
o método A, e de 0,3-3,0 μg/mL, para o método B, respectivamente. Os métodos desenvolvidos foram 
aplicados para o teste de OFX em comprimidos e os resultados foram comparados estatisticamente com 
aqueles do método de referência. A precisão e a confiabilidade dos métodos foram, posteriormente, 
verificadas por meio dos testes de recuperação via método de adição de padrão. 
Unitermos: Ofloxacino/determinação. Titulometria/análise quantitativa. Espectrofotometria/análise 
quantitativa. N-Bromossuccinimida. Comprimidos/análise quantitativa.
INTRODUCTION
Ofloxacin (OFX), (RS)-7-fluoro-2-methyl-6-(4-me-
thylpiperazine-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.05,13]
trideca-5(13),6,8,11-tetraene-11-carboxylic acid (Figu-
re 1), is a fluoroquinolone antibiotic considered to be a 
second-generation fluoroquinolone. It is active against both 
Gram-positive and Gram-negative bacteria and functions 
by inhibiting DNA gyrase, a type II topoisomerase, and 
topoisomerase IV, (Drlica, Zhao, 1997) which is an enzyme 
necessary to separate replicated DNA, thereby inhibiting 
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cell division. This drug is official in the United States Phar-
macopoeia (USP, 2004) and the British Pharmacopoeia (BP, 
2003), which recommend non-aqueous titrimetry (USP, 
2004; BP, 2003) and HPLC (USP, 2004) techniques for its 
assay in bulk and dosage forms.
A review of the literature revealed that various 
analytical methods for the determination of OFX in bulk 
and pharmaceutical dosage forms have been reported. 
These include spectrofluorometry (Salem, 2005), ato-
mic absorption spectrometry (Salem, 2005), capillary 
electrophoresis (Abdalla et al., 2008; Sun, Wu, 1999), 
HPLC (Arjekar et al., 1996; Carlucci et al., 1993; Kalta, 
Sharma, Chaturvedi, 2008; Sinde, Desai, Tendolkar, 
1998), HPTLC (Srividya, Cardoza, Amin, 2003), chemi-
luminescence (Francis, Paul, Adcock, 2005), as well as 
electroanalytical (Tamer, 1990; Tuncel, Atkosar, 1992; 
Zhou, Pan, 1995) and microbiological methods (Silveria, 
Schapoval, 2002). Some of these methods have sufficient 
sensitivity to determine lower concentrations of the 
drug. However, these methods involve several manipu-
lation steps which are not simple for routine analysis of 
pharmaceutical formulations and require sophisticated 
instruments.
Titrimetry and visible spectrophotometry may serve 
as useful alternatives to many of the aforesaid sophistica-
ted techniques because of their cost-effectiveness, ease of 
operation, sensitivity, remarkable accuracy, precision and 
wide applicability. The literature search revealed that no 
titrimetric methods have yet been reported for the deter-
mination of OFX.
Visible spectrophotometric methods based on 
diverse reaction chemistry have been proposed for the 
assay of OFX in pharmaceuticals. The method based on 
the formation of pink colored chromogen by the reaction 
between OFX and citric acid-acetic anhydride (Patel et al., 
2007) has been reported. Extractive spectrophotometric 
procedures based on the formation of yellow colored ion 
pair complex (Issa, 1997) with bromophenol blue (BPB), 
bromothymol blue (BTB) and bromocresol purple (BCP); 
and red colored ion-pair complex (Sastry, Rama, Siva 
Prasad, 1995) with tropaeolin and supracene violet 3B, 
have been used for the assay of OFX. Other visible spec-
trophotometric methods based on reactions such as com-
plex formation reaction with Fe (III) nitrate nonahydrate 
(Eboka, Aigbavboa, Akerele, 1997), yellow complex with 
iron (III) chloride in HCl medium (Mathur et al., 1992); 
and oxidative coupling reaction with Ce(IV)-MBTH 
(Sastry, Rama, Siva Prasad, 1995), were reported for the 
assay of OFX. Most of the visible spectrophotometric 
methods above have one or more inherent disadvantages 
such as use of heating step, use of organic solvents, close 
pH control, poor sensitivity and use of expensive reagents, 
as indicated in Table I.
The aim of the present investigation was to deve-
lop simple, sensitive and cost-effective methods for the 
determination of OFX in pure and dosage forms using 
titrimetric and spectrophotometric techniques. The me-
thods utilized NBS, indigo carmine and metanil yellow 
as reagents. The methods developed offer the advantages 
of simplicity, sensitivity, speed, accuracy and precision 
without the need for costly equipment/chemicals.
MATERIAL AND METHODS
Apparatus
All absorbance measurements were taken on a Systro-
nics model 106 digital single beam spectrophotometer (Ah-
medabad, India) equipped with 1-cm matched quartz cells.
Material and reagents
All chemicals and reagents used were of analytical 
or pharmaceutical grade and distilled water was used to 
prepare the solutions.
· Standard OFX Solution
Pharmaceutical grade OFX, certified to be 99.98% 
pure, was received as a gift from Cipla India Ltd, Mum-
bai, India, and used as received. Standard OFX solutions 
(1 mg/mL, 10 and 6 µg/mL) were prepared by dissolving 
a calculated quantity of pure drug in 0.1 M HCl. 
Two brands of tablets containing OFX, Zenflox-400 
(Mankind Pharma Pvt Ltd., New Delhi, India) and Oflo-
xin-400 (J. B. Chemicals and Pharmaceuticals Ltd, Mum-
bai, India), used in the investigation were purchased from 
local commercial sources.
N-Bromosuccinimide (NBS): an approximately 
0.02 M NBS solution was prepared, standardized (Berka, 
Vulterin, Zyoka, 1965) and used in titrimetry. The NBS 
solution (0.02 M) was further diluted to a concentration 
of 150 and 100 µg/mL for spectrophotometric method A 
and method B, respectively.
FIGURE 1 - Chemical structure of OFX.
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TABLE I - Comparison of performance characteristics of present methods with published methods
Sl. 
No.
Reagent/s used Methodology lmax
(nm)
Linear range 
(µg/mL)
(ε = L/mol/cm)
Remarks Ref
1 Citric acid-acetic anhydride
Pink colored 
chromogen measured
552
5-55
(ε= 6.04 x 103)
Boiling for 20 min 
required.
Patel et al., 
2007
2
a) Bromophenol blue Yellow colored 1:1 
ion-pair complex 
extractable in 
chloroform was 
measured
410
5-25
(ε= 1.04 x 104) Required close pH 
control and involved 
extraction steps organic 
solvent is used
Issa, 1997b) Bromothymol blue 415
2-15
(ε= 2.01 x 104)
c) Bromocresol purple 410
2-20
(ε= 1.04 x 104)
3
a) Tropaeolin 000 (TP 000)
Red colored ion-pair 
complex  extractable 
in chloroform was 
measured
485
2.5-30
(ε= 8.24 x 103) Used of organic 
solvent, required 
close pH control and 
involved extraction 
steps 
Sastry, Rama, 
Siva prasad, 
1995b) Supracene Violet 3B (SV 
3B)
Chloroform 
extractable ion-pair 
complex measured
575
2.5-25
(ε= 1.09 x 104)
4 Iron(III) nitrate
Amber colored 
complex was measured
370
0-62.5
(A1% = 207)
Buffers used.
Eboka, 
Aigbavboa, 
Akerele, 1997
5 Iron(III) chloride/HCl
Yellow complex 
measured
410 20-160
Less sensitive, 
significant blank 
absorbance.
Mathur et al., 
1992
6 Ce(IV)-MBTH
Oxidative coupling 
reaction product 
measured
640 1-10
Uses expensive 
reagent, less stable 
species measured.
Sastry, Rao, 
Prasad, 1995
7
NBS
    a) indigo carmine
Increase in absorbance 
of blue color measured
610
0.5-5.0
(ε= 5.53 x 104)
Highly sensitive, no 
heating or extraction 
step, inexpensive 
instrumental setup, 
use of eco-friendly 
chemicals, and free 
from use of organic 
solvents
Present work
    b) metanil yellow
Increase in absorbance 
of pink color measured
530
0.3-3.0
(ε= 9.24x104)
· Sodium thiosulphate (0.04 M)
This was prepared by dissolving 9.93g of chemical 
(S. d. Fine Chem. Ltd., Mumbai, India) in one liter of water 
for use in titrimetry.
· HCl (1 M, 2 M and 5 M)
Concentrated HCl (S. D. Fine Chem, Mumbai, India, 
sp. gr. 1.18) were appropriately diluted with water to attain 
the required concentrations.
· Potassium iodide (10%)
This was prepared by dissolving 10 g of the chemical 
(Merck, Mumbai, India) in 100 mL of water and used in 
titrimetry.
· Starch indicator (1%)
One g of the reagent (Merck, Mumbai, India) was 
made into a paste and poured into 100 mL of boiling water, 
boiled for 1 min, cooled and used for titrimetry.
· Indigo carmine (200 µg/mL) and metanil yellow 
(50 µg/mL)
The dye solutions were prepared (S.D. Fine Chem, 
Mumbai, India, dye content 90%) in water and filtered.
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General procedure
· Titrimetry
Different volumes (1-8 mL) of standard solution 
containing 1 mg/mL OFX were accurately measured and 
transferred into a 100 mL titration flask and the volume 
was made up to 10 mL with 0.1 M HCl. Two mL of 2 M 
HCl and 10 mL of NBS (0.02 M) were pipetted into the 
flask, the content mixed and set aside for 10 min. Sub-
sequently, 5 mL of 10% potassium iodide solution was 
added, and the liberated iodine was titrated against sodium 
thiosulphate (0.04 M) using starch indicator. A blank titra-
tion was performed under identical conditions.
The amount of OFX in the aliquot was computed 
from the following formula:
 Amount (mg) = VMwS/n (1)
where V = mL of NBS reacted; Mw = relative molecular 
mass of drug; S = concentration of NBS, moles/L; n = 
number of moles of NBS reacting with each mole of OFX.
Spectrophotometry
· Method A
Different aliquots, 0.5, 1.0, 2.0, 3.0, 4.0 and 5.0 mL 
of standard OFX solution (10 µg/mL) were transferred 
into a series of 10 mL standard volumetric flasks and the 
total volume in each flask was adjusted to 5 mL with 0.1 M 
HCl. To each flask, 1 mL of 1M HCl followed by 1 mL 
of 150 µg/mL NBS were added. The content of each flask 
was mixed well and set aside for 15 minutes with occasio-
nal shaking. Finally, 1 mL of 200 µg/mL indigo carmine 
was added and the volume was made up to the mark with 
distilled water after 5 min. The absorbance was measured 
at 610 nm Vs reagent blank prepared in a similar manner.
· Method B
Different aliquots (0.5, 1.0, 2.0, 3.0, 4.0 and 5.0) mL 
of standard 6 µg/mL OFX solution were accurately measu-
red and transferred into a series of 10 mL calibrated flasks 
by means of a microburette and total volume adjusted to 
5 mL with 0.1 M HCl. To each flask, 1 mL of 5 M HCl 
followed by 1 mL of 100 µg/mL NBS, was added using 
a microburette. The content of each flask was mixed well 
and set aside for 10 minutes. Lastly, 1 mL of 50 µg/mL 
metanil yellow was added to each flask and mixed well. 
The volume was made up to the mark with distilled water 
after 5 min and the absorbance was measured at 530 nm 
Vs reagent blank prepared in a similar manner.
Calibration graphs were prepared by plotting the 
increasing absorbance values versus concentrations of 
OFX. The concentration of the unknown was read from 
the respective calibration graph or deduced from the re-
gression equation derived using the Beer’s law data.
Procedure for the assay of ofloxacin in pharmaceutical 
preparations
Twenty tablets were weighed accurately and ground 
into a fine powder. A quantity of the powder containing 
100 mg of OFX was accurately weighed into a 100 mL 
calibrated flask and 60 mL of 0.1 M HCl was added. The 
content was shaken for about 20 min; volume diluted to 
the mark with 0.1 M HCl and mixed, and filtered using a 
Whatman No. 42 filter paper. The first 10 mL portion of 
the filtrate was discarded, and a convenient aliquot was 
taken and the assay completed according to the titrimetric 
procedure described earlier. The tablet extract containing 
OFX at a concentration of 1 mg/mL was then diluted ste-
pwise with 0.1 M HCl to obtain working concentrations 
of 10 μg/mL and 6 μg/mL in OFX for spectrophotometric 
methods A and B, respectively. A convenient aliquot was 
then subjected to analysis by the spectrophotometric pro-
cedures described above.
Placebo blank analysis
Based on the approximate composition of excipients 
normally added in the tablet, a placebo blank of the com-
position: talc (5 mg), starch (5 mg), acacia (5 mg), methyl 
cellulose (10 mg), sodium citrate (5 mg), magnesium 
stearate (5 mg) and sodium alginate (5 mg) was made and 
its solution prepared as described under ‘Procedure for the 
assay of OFX in pharmaceutical preparations’, and then 
subjected to analysis using the procedures described above.
Procedure for the determination of OFX in synthetic 
mixture
A volume of 100 mg of OFX was added to the pla-
cebo blank of the composition described above, which 
was then homogenized, transferred to a 100 mL standard 
flask and solution prepared as described under tablets. The 
solution was mixed well and filtered using a Whatman No. 
42 filter paper. The resulting solution was assayed (n=5) 
by titrimetry according to the procedure described above. 
The synthetic mixture solution (1 mg/mL in OFX) was 
then diluted stepwise with 0.1 M HCl to obtain working 
concentrations of 10 μg/mL and 6 μg/mL in OFX for 
spectrophotometric method A and method B, respectively. 
A convenient aliquot was then subjected to analysis. The 
analysis was used to study the interferences of excipients 
such as talc, starch, acacia, methyl cellulose, sodium ci-
trate, magnesium stearate and sodium alginate.
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RESULTS AND DISCUSSION
A close examination of the literature search pre-
sented in the introduction reveals that NBS has not yet 
been used for the spectrophotometric determination of 
OFX. NBS is a strong oxidizing agent and perhaps the 
most important positive bromine containing organic 
compound; it is used for the specific purpose of bromi-
nating alkenes at the allylic position (Morrison, Boyd, 
2007). The present work involves the bromination of 
OFX by NBS followed by determination of surplus 
NBS after allowing the bromination reaction to com-
plete. In titrimetry, the unreacted NBS is determined 
iodometrically, while in spectrophotometric methods, 
it is determined by reacting with a fixed amount of 
either indigo carmine and measured at 610 nm (Fi-
gure 2) or metanil yellow and measured at 530 nm 
(Figure 2). The spectrophotometric methods make use of 
the bleaching action of NBS on either of the two dyes, 
where the discoloration is caused by oxidative destruc-
tion of the dye. The tentative reaction scheme of titrime-
tric and spectrophotometric methods methods is shown in 
FIGURE 2 - Absorption spectra (4.0 µg/mL OFX in method A and 2.4 µg/mL in method B).
SCHEME I - Tentative reaction scheme for titrimetry, spectrophotometric method A and method B.
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Scheme 1. The bromination of OFX will take place in 
position α to the carbonyl group (Hassan et al., 2007).
Titrimetry
Direct titration of OFX with NBS in acid medium 
was not successful. However, a back titrimetric assay was 
found to be possible when the reactants were allowed to 
stand for some time in acid medium. The reaction stoi-
chiometry was found to be 1:5 (OFX: NBS). Reproduci-
ble and stoichiometric results were obtained when HCl 
medium was employed. A two mL volume of 2M HCl 
in a total volume of 22 mL (0.18 M) was found optimal; 
although the stoichiometry reaction was unaffected in the 
concentration range of 0.09-0.27 M HCl. The bromination 
reaction was found to be complete and quantitative in 10 
min and contact time up to 20 min had no effect on the 
stoichiometry or the results. Hence, the reaction time of 
10 min was established. A 10 mL aliquot of 0.02 M NBS 
solution was found adequate for quantitative bromination 
of OFX in the range determined of 1-8 mg.
Spectrophotometric methods
The ability of NBS to brominate OFX and bleach 
the colors of indigo carmine and metanil yellow dyes 
has been used for the indirect spectrophotometric assay 
of the drug. Preliminary experiments were performed to 
determine the maximum concentration of indigo carmine 
or metanil yellow in the acid medium employed where this 
was found to be 20 µg/mL and 5 µg/mL for indigo carmine 
and metanil yellow, respectively. An NBS concentration 
of 15 µg/mL was found optimum to bleach the blue color 
produced by 20 µg/mL indigo carmine, whereas in the 
case of metanil yellow, 10 µg/mL NBS was sufficient to 
destroy the pink color of 5 µg/mL metanil yellow. Hence, 
different amounts of OFX reacted with 15 µg/mL NBS in 
method A, and 10 µg/mL NBS in method B.
Hydrochloric acid was found to be the ideal me-
dium for the bromination of OFX by NBS as well as 
the latter’s determination employing either dye. In both 
the methods, the reaction between OFX and NBS was 
unaffected when 0.5-3.0 mL each of 1 M HCl (method 
A) and 5M HCl (method B) in a total volume of 10 mL 
was used. Hence, 1 mL each of 1 M HCl in method A 
and 5M HCl in method B was used for both the steps. 
For a quantitative reaction between OFX and NBS, con-
tact times of 15 min and 10 min were found necessary 
in method A and method B, respectively, and constant 
absorbance readings were obtained when contact times 
were extended up to 45 min in method A, and 30 min in 
method B. A standing time of 5 min was necessary in 
both the methods for the bleaching of the dye color by 
the residual NBS. The measured color was found to be 
stable for several hours in the presence of the reaction 
products in both methods.
Method validation procedures
The proposed methods have been validated for 
linearity, sensitivity, precision, accuracy, selectivity and 
recovery.
Linearity and Sensitivity
Over the range investigated (1-8 mg), fixed stoichio-
metry of 1:5 (OFX: NBS) was obtained in titrimetry, which 
served as the basis for calculations. In spectrophotometry, 
under optimum conditions a linear relation was obtained 
between absorbance and concentration of OFX in the 
range of 0.5-5.0 µg/mL (method A) and 0.3-3.0 µg/mL 
(method B) (Figure 3). The calibration graph is described 
by the equation:
 Y = a + b X  (2)
(where Y = absorbance, a = intercept, b = slope and X = 
concentration in µg/mL) obtained by the method of least 
squares. Correlation coefficient, intercept and slope for 
the calibration data are summarized in Table II. Sensiti-
vity parameters such as apparent molar absorptivity and 
FIGURE 3 - Calibration curves for (a) method A and (b) method B).
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TABLE II - Sensitivity and Regression Parameters
Parameter Method A Method B
lmax, nm 610 530
Linear range, µg/mL 0.5-5.0 0.3-3.0 
Molar absorptivity(ε), L /mol/cm 5.534 x 104 9.242 x 104
Sandell sensitivity*, µg/cm2 0.007 0.004
Limit of detection (LOD), mg/mL 0.03 0.03
Limit of quantification (LOQ), mg/mL 0.09 0.08
Regression equation, Y**
Intercept (a) 0.003 0.003
Slope (b) 0.152 0.237
Standard deviation of a (Sa) 0.0104 0.0774
Standard deviation of b (Sb) 0.004 0.046
Regression coefficient (r) 0.998 0.999
*Limit of determination as the weight in µg per ml of solution, which corresponds to an absorbance of A = 0.001 measured in 
a cuvette of cross-sectional area 1 cm2 and l = 1 cm. **Y=a+bX, Where Y is the absorbance, X is concentration in µg/mL, a is 
intercept, b is slope.
TABLE III - Evaluation of intra-day and inter-day accuracy and precision
Methoda OFX 
taken
Intra-day accuracy and precision Inter-day accuracy and precision
OFX found %RE %RSD OFX found %RE %RSD
Titrimetry 2.0 2.03 1.50 1.06 2.05 2.5 1.32
4.0 4.05 1.25 1.01 4.11 2.75 0.97
6.0 5.94 1.00 0.95 5.85 2.50 1.18
Spectrophotometry
Method A 2.0 1.96 2.00 0.92 1.94 3.00 1.15
3.0 3.03 1.00 1.14 3.10 3.33 1.28
4.0 4.12 3.00 1.02 3.89 2.75 1.11
Method B 1.2 1.23 2.50 1.14 1.24 3.33 1.35
1.8 1.76 2.22 1.19 1.75 2.78 1.23
2.4 2.34 2.50 1.21 2.32 3.33 1.29
RE. Relative error and RSD. Relative standard deviation. aIn titrimetry, OFX taken/found are in mg, whereas for spectrophotometry 
values are µg/mL.
Sandell’s sensitivity values, as well as the limits of detec-
tion and quantification, were calculated as per the current 
ICH guidelines (ICH guidelines, 2005) and compiled in 
Table II. The results attest to the sensitivity of the proposed 
method. The limits of detection (LOD) and quantification 
(LOQ) were calculated according to the same guidelines 
using the formulae:
 LOD=3.3σ/s and LOQ=10σ/s  (3)
where σ is the standard deviation of five reagent blank 
determinations, and s is the slope of the calibration curve.
Precision and accuracy
In order to evaluate the precision of the proposed 
methods, solutions containing three different concen-
trations of the OFX were prepared and analyzed in five 
replicates. The analytical results obtained from this inves-
tigation are summarized in Table III. The low values of 
the relative standard deviation (% R.S.D) and percentage 
relative error (% R.E) indicate the precision and accuracy 
of the proposed methods. The percentage relative error is 
calculated using the following equation:
 
  (4)
The assay procedure was repeated seven times, 
and percentage relative standard deviation (% R.S.D) 
values were obtained within the same day to evaluate 
repeatability (intra-day precision), and over five diffe-
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rent days to evaluate intermediate precision (inter-day 
precision).
Selectivity
The proposed methods were tested for selectivity 
by placebo blank and synthetic mixture analyses. A con-
venient aliquot of the placebo blank solution, prepared as 
described earlier, was subjected to analysis by titrimetry 
and spectrophotometry according to the recommended 
procedures. In all the cases, there was no interference by 
the inactive ingredients present in the placebo mixture.
A separate experiment was performed with the syn-
thetic mixture. The analysis of synthetic mixture solution 
prepared above yielded percent recoveries which ranged 
from 97.72-102.9 with standard deviation of 0.95-1.23 in 
all the cases. The results of this study shown in Table IV 
indicate that the inactive ingredients present in the syn-
thetic mixture did not interfere in the assay. These results 
further demonstrate the accuracy, as well as the precision, 
of the proposed methods.
Application to formulations
In order to evaluate the analytical applicability of 
the proposed methods to the quantification of OFX in 
commercial tablets, the results obtained by the proposed 
methods were compared to those of the reference method 
(BP, 2003) by applying Student’s t-test for accuracy and 
the F-test for precision. The reference method involved 
the titration of OFX in anhydrous acetic acid with acetous 
perchloric acid to potentiometric end point detection. 
The results (see Table V) show that the Student’s t- and 
F-values at a 95 % confidence level are lower than the 
tabulated values, thereby confirming good agreement 
between the results obtained by the proposed methods 
and the reference method, with respect to accuracy and 
precision.
Recovery studies
The accuracy and validity of the proposed methods 
were further ascertained by performing recovery studies. 
Pre-analysed tablet powder was spiked with pure OFX at 
three concentration levels (50, 100 and 150% of that in 
tablet powder) and totals then determined by the proposed 
methods. In all cases, the added OFX recovery percentage 
values ranged from 98.50-102.5% with a standard devia-
tion of 1.03-1.24 (Table VI), indicating good recovery and 
absence of interference from the co-formulated substance 
in the determination.
CONCLUSIONS
The proposed titrimetric method is a first report on 
the application of titrimetry for the assay of OFX. The 
TABLE IV - Recovery of drug from synthetic mixture
Method
OFX in 
synthetic 
mixture takena
OFX recoveredb 
(Percent ±SD)
Titrimetry 2.0 102.4 ± 1.23
4.0 101.7 ± 1.21
6.0 102.9 ±1.18
Spectrophotometry
Method A 2.0 97.84 ± 1.14
3.0 98.18 ± 1.09
4.0 97.72 ± 0.95
Method B 1.2 99.68 ± 1.12
1.8 100.9 ± 1.07
2.4 99.17 ± 1.18
amg in titrimetry and µg/mL in spectrophotometry. bMean value 
of five determinations
TABLE V - Results of analysis of tablets by proposed methods
Tablet Brand 
name
Label claim,
mg/tablet
Found* (Percent of label claim ± SD)
Reference 
method
Titrimetry
Spectrophotometry
Method A Method B
Zenflox-400** 20 100.12 ± 1.09
102.0 ± 1.17
t= 2.62
F= 1.15
98.12 ±1.29
t=2.65
F= 1.40
98.87 ± 1.15
t=1.76
F= 1.11
Ofloxin-400*** 20 100.4 ± 1.02
101.7 ± 1.04
t= 1.99
F= 1.04
98.95 ± 1.32
t=1.96
F=1.67
102.1 ± 1.13
t=2.49
F=1.23
*Mean value of five determinations. ** Mankind Pharma Pvt Ltd., New Delhi, India;*** J. B. Chemicals and Pharmaceuticals Ltd, 
Mumbai, India. The value of t (tabulated) at 95 % confidence level and for four degrees of freedom is 2.77. The value of F (tabulated) 
at 95% confidence level and for four degrees of freedom is 6.39.
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TABLE VI - Accuracy assessment by recovery experiments
Method Tablet studied OFX in tablet* Pure OFX added* Total found*
Pure OFX 
recovered** 
Percent ± SD
Titrimetry Ofloxin-400 3.05 1.5 4.57 101.3 ±1.03
3.05 3.0 6.07 100.7 ± 1.08
3.05 4.5 7.54 99.78 ± 1.17
Spectrophotometry
Method A Ofloxin-400 1.98 1.0 2.97 99.00 ± 1.24
1.98 2.0 3.95 98.50 ± 1.07
1.98 3.0 4.97 99.67 ± 1.03
Method B Ofloxin-400 1.22 0.6 1.83 101.6 ± 1.15
1.22 1.2 2.45 102.5 ± 1.04
1.22 1.8 3.05 101.7 ± 1.11
 *mg in titrimetry and µg/mL in spectrophotometry. **Mean value of three measurements.
titrimetric method is straightforward and fast compared to 
the other methods reported earlier. The proposed methods 
make use of simple reagent, which an ordinary analytical 
laboratory can afford and, unlike most currently available 
spectrophotometric methods, the present methods are free 
from unwelcome steps such as heating or extraction and 
also from critical pH conditions. The spectrophotometric 
methods are the most sensitive reported to date for OFX 
(Table I). The methods are also useful for their high tole-
rance limit for common excipients found in drug formu-
lations. These merits, coupled with the use of simple and 
inexpensive instruments, allow recommendation of the use 
of these methods in routine quality control Laboratories.
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